Patent Board Sides With Patent Owner In Final Written Decision

Mealey's (February 8, 2018, 8:54 AM EST) -- ALEXANDRIA, Va. — A patented method for treating inflammatory autoimmune diseases with a high concentration subcutaneous methotrexate formulation was confirmed as patentable on Feb. 7 by the Patent Trial and Appeal...

To view the full article, register now.